miR-331-3p在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2018.02.007

摘要/Abstract

摘要： miRNA是一种存在于真核生物细胞中的一类内源性非编码的RNA小分子,miR-331-3p作为miRNA家族中的一员,在细胞生理过程中发挥重要作用。近年来,miR-331-3p在恶性肿瘤中的作用日益受到关注。已有研究显示,miR-331-3p在宫颈癌、肝癌、胶质母细胞瘤及前列腺癌等恶性肿瘤的发生发展及复发转移过程中均发挥着重要作用。这些研究结果对恶性肿瘤的诊断及预后起到帮助作用。

关键词: miR-331-3p, 恶性肿瘤, 基因表达

Abstract: miRNA is a small class of endogenous non-coding RNA molecules that exist in eukaryotic cells.miR-331-3p is a member of miRNA family,which plays an important role in the physiological process.In recent years,effects of miR-331-3p on malignant tumors have been increased attention.Studies have demonstrated that miR-331-3p plays an important role in the development,recurrence and metastasis of malignant tumors such as cervical cancer,liver cancer,glioblastoma and prostate cancer.These findings contribute to help the diagnosis and prognosis of malignant tumors.

Key words: miR-331-3p, Malignant tumor, Gene expression

中图分类号:

李静,张云艳. miR-331-3p在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 125-129.

LI Jing, ZHANG Yunyan. Research progress of miR-331-3p in malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 125-129.

参考文献

1 Lund E,Guttinger S,Calado A,et al.Nuclear export of microRNA precursors[J].Science,2004,303(5654):95-98.
2 Taylor MA,Schiemann WP.Therapeutic opportunities for targeting microRNAs in cancer[J].Mol Cell Ther,2014,2(30):1-13.
3 Kojima M,Sudo H,Kawauchi J,et al.MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers[J].PLoS One,2015,10(2):e0118220.
4 Lujambio A,Lowe SW.The microcosmos of cancer[J].Nature,2012,482(7385):347-355.
5 Winter J,Jung S,Keller S,et al.Many roads to maturity:microRNA biogenesis pathways and their regulation[J].Nat Cell Biol,2009,11(3):228-234.
6 Petri A,Lindow M,Kauppinen S.MicroRNA silencing inpri-mates:towards development of novel therapeutics[J].Cancer Res,2009,69(2):393-395.
7 Epis MR,Giles KM,Barker A,et al.miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer[J].J Biol Chem,2009,284(37):24696-24704.
8 Maes OC,Sarojini H,Wang E,et al.Stepwise up-regulation of microRNA expression levels from replicating to reversible and irreversible growth arrest states in WI-38 human fibroblasts[J].Cell Physiol,2009,221(1):109-119.
9 Guo X,Guo L,Ji J,et al.miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer[J].Biochem Biophys Res Commun,2010,398(1):1-6.
10 Zhao D,Sui Y,Zheng X.miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer[J].Oncol Rep,2016,35(2):1075-1082.
11 Epis MR,Barker A,Giles KM,et al.The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer[J].Cells,2011,286(48):41442-41454.
12 Epis MR,Giles KM,Candy PA,et al.miR-331-3p regulates expression of neuropilin-2 in glioblastoma[J].Neurooncol,2014,116(1):67-75.
13 Chang RM,Yang H,Fang F,et al.MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting pH domain and leucine-rich repeat protein phosphatase[J].Hepatology,2014,60(4):1251-1263.
14 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
15 Fujii T,Shimada K,Asano A,et al.MicroRNA-331-3p suppresses cervical cancer cell proliferation and E6/E7 expression by targeting NRP2[J].Int J Mol Sci,2016,17(8):1351.
16 Muñoz N,Castellsagué X,de González AB,et al.Chapter 1:HPV in the etiology of human cancer[J].Vaccine,2006,24(3):1-10.
17 Hausen H.Papilloma viruses causing cancer?:Evasion from host-cell control in early events in carcinogenesis[J].Natl Cancer Inst,2000,92(9):690-698.
18 Imamura Y,Sadar MD.Androgen receptor targeted therapies in castration-resistant prostate cancer:bench to clinic[J].Int J Urol,2016,23(8):654-665.
19 Bartel DP.MicroRNAs:target recognition and regulatory functions[J].Cell,2009,136(2):215-233.
20 Thieu W,Tilki D,RW deVere White R,et al.The role of microRNA in castration-resistant prostate cancer[J].Urol Oncol,2014,32(5):517-523.
21 Jung HS,Rajasekaran N,Song SY,et al.Human papillomavirus E6/E7-specific siRNA potentiates the effect of radiotherapy for cervical cancer in vitro and in vivo[J].Int J Mol Sci,2015,16(6):12243-12260.
22 White NM,Youssef YM,Fendler A,et al.The miRNA-kallikrein axis of interaction:A new dimension in the pathogenesis of prostate cancer[J].Biol Chem,2012,393(5):379-389.
23 Epis MR,Giles KM,Kalinowski FC,et al.Regulation of expression of deoxyhypusine hydroxylase(DOHH),the enzyme that catalyzes the activation of eIF5A,by miR-331-3p and miR-642-5p in prostate cancer cells[J].Biol Chem,2012,287(42):35251-35259.
24 Epis MR,Giles KM,Beveridge DJ,et al.miR-331-3p and Aurora kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression[J].Oncotarget,2017,8(33):55116-55134.
25 McGlynn KA,London WT.The global epidemiology of hepatocellular carcinoma:present and future[J].Clin Liver Dis,2011,15(2):223-243.
26 Chang RM,Yang H,Fang F,et al.MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase[J].Hepatology,2014,60(4):1251-1263.
27 Cao YY,Chen J,Wang D,et al.Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells,miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5[J].Oncotarget,2015,6(35):38093-38106.
28 Xing YN,Yang X,Xu XY,et al.The altered expression of ING5 protein is involved in gastric carcinogenesis and subsequent progression[J].Hum Pathol,2011,42(1):25-35.
29 Cengiz B,Gunduz E,Gunduz M,et al.Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma[J].Int J Cancer,2010,127(9):2088-2094.
30 Coburn NG.Lymph nodes and gastric cancer[J].Surg Oncol,2009,99(4):199-206.
31 Liu XH,Sun M,Nie FQ,et al.Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer[J].Mol Cancer,2014,13(1):92.
32 Gupta RA,Shah N,Wang KC,et al.Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis[J].Nature,2010,464(7291):1071-1076.
33 Fakhari M,Pullirsch D,Abraham D,et al.Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and-2 in human neuroblastoma[J].Cancer,2002,94(1):258-263.
34 Wang L,Oberg AL,Asmann YW,et al.Genome-wide transcyiptional profiling reveals microRNA-correlated genes and biological process in human lymphoblastoid cell lines[J].PLoS One,2009,4(6):e5878.
35 De Martino I,Visone R,Fedele M,et al.Regulation of microRNA expression by HMGA1 proteins[J].Oncogene,2009,28(11):1432-1442.

[1]	李吉, 陈杨, 张茂镕, 杨昭, 唐娴, 文洪梅. 中国常见消化系统恶性肿瘤伤残调整寿命年归因于人口老龄化的比例分析和趋势预测[J]. 实用肿瘤学杂志, 2025, 39(5): 372-380.
[2]	周素霞, 许志华, 郭淑玲, 范宁, 徐莉立. 2014—2021年青海省肿瘤登记地区恶性肿瘤发病与死亡流行趋势分析[J]. 实用肿瘤学杂志, 2025, 39(5): 381-387.
[3]	刘洋, 王颖, 马祥, 宋家宝, 刘大民, 陈丽莉. 2021年辽宁省营口市城市居民恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2025, 39(5): 400-404.
[4]	代晓泽, 马玉霞, 李雨婷, 齐笑晴, 祝天岑, 穆慧娟, 刘辉. 2014—2020年辽宁省阜新市城市居民恶性肿瘤发病与死亡流行趋势分析[J]. 实用肿瘤学杂志, 2025, 39(4): 278-283.
[5]	祝天岑, 礼彦侠, 任方晗, 代晓泽, 刘洋, 穆慧娟. 2021年辽宁省肿瘤登记地区恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2025, 39(4): 294-300.
[6]	李吉, 张茂镕, 杨昭, 文洪梅, 伍福仙, 李云涛. 2020年云南省昆明市肿瘤登记地区恶性肿瘤发病和死亡特征及2016—2020年趋势分析[J]. 实用肿瘤学杂志, 2025, 39(3): 169-176.
[7]	文小焱, 陈俐. 2010年和2020年四川省30岁及以上人群恶性肿瘤疾病负担比较分析[J]. 实用肿瘤学杂志, 2025, 39(1): 1-6.
[8]	陈茂森, 陈杨, 石青萍, 邵英, 唐娴, 任思颖, 文洪梅. 2020年云南省恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2024, 38(5): 283-288.
[9]	苏锋, 梁磊, 邓英, 张同蕾, 王艳平. 2016—2020年陕西省安康市恶性肿瘤流行特征和变化趋势分析[J]. 实用肿瘤学杂志, 2024, 38(5): 300-305.
[10]	何佳颖, 朱津丽, 贾凯旋, 杨佩颖. IFN-γ在肿瘤免疫检查点抑制剂治疗中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 330-335.
[11]	刘丽莉, 张雪云, 张雷. 2020—2022年第一师阿拉尔市恶性肿瘤发病分析[J]. 实用肿瘤学杂志, 2024, 38(4): 246-253.
[12]	钟女娟, 马晶昱, 许志达. 2019年福建省福清市恶性肿瘤发病与死亡情况及2015—2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(1): 1-6.
[13]	程锦, 王玮. 维甲酸诱导蛋白在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 502-506.
[14]	赵世博, 陈永峰, 黎惠怡, 符爱珍. Agrin参与恶性肿瘤发生发展的研究现状[J]. 实用肿瘤学杂志, 2023, 37(6): 507-512.
[15]	宋述铭, 李改琴, 张黎峰, 许凯, 毛雯靖, 张光辉. 新疆医科大学附属肿瘤医院2010—2020年恶性肿瘤住院患者流行病学分析[J]. 实用肿瘤学杂志, 2023, 37(5): 389-394.